OncoMatch/Clinical Trials/NCT05304234
Liver Cancer Disparities in American Indian and Alaska Native Persons
Is NCT05304234 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Lab requirements
Kidney function
GFR<30 excluded
Liver function
CTP score >=10 excluded; MELD-Na score >20 excluded
CTP score >=10; MELD-Na score >20; GFR<30
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Cherokee Nation Health Service · Tahlequah, Oklahoma
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify